There are 807 resources available
367P - High-dose aumolertinib in EGFR-mutant NSCLC patients with brain metastases: Primary data from ACHIEVE
Presenter: Yun Fan
Session: Poster viewing 05.
368P - A special Imaging pattern of bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs
Presenter: Zhen-Bang Gu
Session: Poster viewing 05.
370P - Outcomes in patients with EGFR-mutant locally advanced or metastatic NSCLC co-mutations receiving aumolertinib as first-line treatment: A retrospective study
Presenter: Fang Cun
Session: Poster viewing 05.
371P - Real-world data of first-line treatment with aumolertinib for elderly EGFR+ NSCLC patients
Presenter: Haitao Zhang
Session: Poster viewing 05.
373P - Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
Presenter: WenFeng Fang
Session: Poster viewing 05.
374P - NX-019, a brain penetrant, mutation selective EGFR inhibitor with broad mutant EGFR activity
Presenter: Keith Wilson
Session: Poster viewing 05.
375P - Stereotactic radiotherapy (SRT) in combination with aumolertinib to treat intracranial oligometastatic non-small cell lung cancer (NSCLC): A phase II, prospective study
Presenter: Jiayan Chen
Session: Poster viewing 05.